Bioinformatics for drug development

Discover drug targets, mechanisms and biomarkers with cutting-edge omics data analysis.

Molecular measurements based on next-generation sequencing (NGS) and mass-spectrometry (MS) are routinely used throughout the drug development process. RNA-sequencing and proteomics, in particular, reveal a more detailed view of pathways and functions in disease models and patients.

We work with customers developing small molecules and biologics as well as gene, cell and biomaterial therapies. Learn more about the stages in drug development that benefit from high-throughput molecular measurements coupled with state-of-the-art bioinformatics, and browse our numerous references!

Leave us a short description of your bioinformatics needs and we will be in touch very soon!

NGS and mass-spec data analysis supports drug development at all stages

Basic research

Basic research into the molecular and cellular biology of a disease is a prerequisite for rational drug discovery. Much of the work our customers outsource to us falls under this category. Read more about our experience in basic research by research areas and data modalities.

Target discovery

Target-based drug development begins at identifying a protein or other biomolecule to use as a target for treatment. The wealth of public, semi-public and proprietary data lends itself to data-driven target discovery. Examples include:

  • Identifying causative genetic variants in genome-wide association studies or genetic studies of families with a hereditary disease.
  • Identifying genes associated to disease progression events from e.g. tumor RNA-sequencing or proteomic data.
  • Identifying genes with disease-specific up- or down-regulation using patient samples or animal models of a disease.
  • Identifying signaling pathways activated or inhibited in a disease.

Target validation

A candidate target can be further studied and validated using gene knock-out models, in vitro or in vivo. Gene expression analysis of such models may reveal both wanted and unwanted downstream effects of a gene knock-out.

Preclinical development

After a candidate drug has been identified against the target, mechanism-of-action and off-target analyses can be performed, again using in vitro or in vivo models. Transcriptomics (RNA-seq), proteomics and epigenomics (e.g., ChIP-seq, ATAC-seq) are particularly applicable high-throughput measurements.

Biomarker discovery

Biomarkers, such as as genetic variants, proteins or metabolites, can be instrumental in stratifying patients based on their predicted likelihood of benefitting from the treatment.

Candidate biomarkers can be identified already before a clinical trial (from e.g., biobank data) to identify high-risk patients.

Molecular measurements during and after a clinical trial, on the other hand, can be used to identify biomarkers for treatment response or side effects (including pharmacogenetic markers).

Learn more

All analyses

References and case studies

All references

Selected publications from our customers

  • Liu, S. et al. (2023). Urolithin A induces cardioprotection and enhanced mitochondrial quality during natural aging and heart failure. bioRxiv 2023.08.22.55437.
  • D’Amico, D. et al. (2023). Topical application of Urolithin A slows intrinsic skin aging and protects from UVB-mediated photodamage: Findings from Randomized Clinical Trials. medRxiv 2023.06.16.23291378.
  • Singh, A. et al. (2022). Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine, 3(5), 100633.
  • Tusup, M. et al. (2022). Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors. Molecular therapy : the journal of the American Society of Gene Therapy, 30(3), 1163–1170.
  • Madonna, G. et al. (2021). Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers, 13(16), 4164.
  • Pernaute-Lau, L. et al. (2021). Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment. Antimicrobial agents and chemotherapy, 65(7), e0027521.
  • Hussey, G. S. et al. (2020). Lipidomics and RNA sequencing reveal a novel subpopulation of nanovesicle within extracellular matrix biomaterials. Science advances, 6(12), eaay4361.
  • Gurvich, O. L. et al. (2020). Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products. Scientific reports, 10(1), 14049.

Selected publications from our team

  • Annala, M. et al. (2021). Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 32(7), 896–905.
  • Viana, J. et al. (2020). Clozapine-induced transcriptional changes in the zebrafish brain. NPJ schizophrenia, 6(1), 3.
  • Mehtonen, J. et al. (2020). Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities. Genome medicine, 12(1), 99.
  • Jylhä, A. et al. (2018). Comparison of iTRAQ and SWATH in a clinical study with multiple time points. Clinical proteomics, 15, 24.

Browse all

Every time I spoke to Genevia, I had a lot of questions that needed clear and accurate answers. It was very satisfying to receive incredibly patient explanations. The communication was faultless! Essentially, the project was a common journey to evolving the data, with a lot of learning on both sides, as Genevia poured in their own ideas while accommodating inputs from our side.

Vikash Reebye
Vikash Reebye Principal Scientist MiNA Therapeutics

I don't have to worry about bioinformatics, because I can leave that to professionals. at the same time, our scientists have learned a lot about bioinformatics and it's possibilities.

Tuija Kekäräinen
Tuija Kekäräinen Research Director KCT

Genevia goes beyond being a simple service provider, providing the scientific input that is comparable to a top academic collaboration.

Davide D’Amico R&D Group Leader Amazentis SA

I was looking for a partner to validate and improve an algorithm that aims to identify the optimal combination of cancer therapy for each patient by assessing clinical data. The collaboration with Genevia’s team has gone without any challenges. Their response time is short, they are easy to communicate with and provide high-quality machine learning expertise.

Giuseppe Masucci M.D. Senior Consultant, Professor Dept. of Oncology-Pathology, Karolinska Institutet

Genevia’s bioinformaticians do not assume every biologist knows how to program. Instead, they were very generous in explaining their workflow and in educating us. With Genevia Technologies, I do not need to compromise my standards of communication, quality, or speed. I tried hard to think of any improvements for Genevia’s services, but I came out with none. That probably says it all.

José Pedro Gil Associate Professor in Molecular Pharmacology Centre for Malaria Research, Karolinska Institute

Contact us

Leave your email address here with a brief description of your needs, and we will contact you to get things moving forward!

Antti Ylipää
Antti Ylipää CEO, co-founder Genevia Technologies Oy +358 40 747 7672